US blocks Chinese biotech, Europe fosters growth: Korea urged to speed up clinical trials and R&D

The United States and Europe are adopting distinct strategies to counter and catch up with China's rapidly expanding biotechnology sector. While the U.S. is concentrating on blocking capital and technology inflow to Chinese biotech companies through "biosecurity laws" and investment restrictions, the European Union is prioritizing the enhancement of its clinical research and development ecosystem.

This divergence in approach sees the U.S. employing a more restrictive stance, aiming to curb the growth of Chinese biotech firms by limiting their access to American funding and technological advancements. This move is seen as a direct response to the increasing global influence and innovation originating from China's life sciences industry.

Conversely, the EU is pursuing a strategy of fostering its domestic capabilities. By investing in and supporting its R&D infrastructure and clinical trial processes, the EU aims to bolster its own competitiveness in the global pharmaceutical market. This approach focuses on building inherent strengths rather than solely on restricting foreign competition.

The article implies that South Korea, facing similar competitive pressures, should also expedite its clinical trials and research and development activities. This call to action suggests that a proactive and accelerated pace in innovation is necessary for South Korea to effectively navigate and compete within the dynamic global biotech landscape.